Objectives: We investigated the risk of virological rebound in HIV-1-infected patients achieving virological suppression on first-line combined ART (cART) according to baseline HIV-1 RNA, time to virological suppression and type of regimen.
Introduction
With modern combined ART (cART), very high rates (.85%-90%) of virological success are observed while virological failures once virological success has been obtained, have become rare, as a result of improved potency, convenience and tolerability of currently used antiretroviral regimens. 1 Time to achieve virological suppression is mainly dependent on baseline HIV-1 RNA plasma level and the type of regimen used, with significantly more rapid suppression in patients with HIV-1 RNA ,100000 copies/mL and/or receiving integrase inhibitor (INI)-containing regimens, as opposed to NNRTI or ritonavir-boosted PI (PI/r)-containing ones. [2] [3] [4] When virological suppression has been obtained on first-line cART, the risk of virological rebound is mainly dependent on tolerability of and adherence to treatment, while pre-cART HIV-1 RNA and CD4 cell counts do not seem to have an impact. 5 The relationship between baseline HIV-1 RNA, time to initial virological suppression and virological rebound, according to the nature of first-line cART has not been characterized in detail. We conducted a nationwide observational study in France to assess the impact of pre-cART baseline HIV-1 RNA and time to virological suppression on virological rebound, comparing the three types of recommended first-line cART, NNRTI-based, PI/r-based or INI-based, each combined with two nucleoside or nucleotide reverse transcriptase inhibitors (NtRTIs).
Patients and methods

Ethics
The study is registered with ClinicalTrials.gov, number NCT02898987. All patients presenting for care in one of the centres gave written consent to be enrolled in the cohort. In accordance with French law, the cohort was approved by the French 'Commission Nationale Informatique et Liberté'.
Study design and patients
The Dat'AIDS Cohort was established in 2000 and includes, as of 1 January 2015, 53000 HIV-1-infected adults in 20 major French HIV treatment centres. 6 Once the patient was enrolled, all clinical events as well as all therapeutic information, biological results and any other relevant information (i.e. demographic details) were prospectively collected via an electronic medical record. This system allows the use of the database with minimal delay, automatic and manual quality controls being performed before any analysis. Plasma HIV-1 RNA and CD4 cell count data were collected at regular intervals during routine clinical assessment (usually every 3-6 months). HIV-1 RNA determinations were done in each local laboratory. HIV-1-infected patients were enrolled in this study if they were aged 18 years, had started a first cART between 1 January 2007 and 31 December 2014 with a combination of three drugs, including two NtRTIs combined with either efavirenz, an INI (raltegravir, elvitegravir/cobicistat or dolutegravir) or ritonavir-boosted atazanavir, darunavir or lopinavir.
The choice of these third agents was based on recommendations for firstline therapy in French guidelines between 2006 and 2014. Rilpivirinecontaining regimens were excluded because their use in first-line therapy is restricted to patients with baseline HIV RNA ,5 log 10 copies/mL. Patients enrolled in a clinical trial were not excluded as long as they were receiving one of the regimens selected for the study.
Endpoint
The endpoint was time to virological rebound in patients achieving virological suppression (HIV-1 RNA ,50 copies/mL) after initiating cART. Virological rebound was defined as the first occurrence of a confirmed HIV-1 RNA .50 copies/mL in two consecutive samples after achieving HIV-1 RNA ,50 copies/mL.
Statistical analyses
We grouped patients according to third agent (efavirenz, PI/r or INI). Baseline CD4! cell counts and HIV-1 RNA were defined as the latest available results in the 6 months before starting treatment. We compared baseline characteristics of patients according to their third agent using Kruskal-Wallis tests for continuous variables and v 2 tests for categorical variables. Kaplan-Meier plots were used to describe the time to virological rebound after virological suppression by baseline HIV-1 RNA, time to virological suppression and third agent. Comparisons between groups were made using the log-rank test. We ignored treatment switches before virological suppression for our analyses. Patients were right-censored at the date of the last follow-up visit. We used Cox proportional hazards regression models, with multiple adjustments, to estimate crude and adjusted associations of baseline HIV-1 RNA and time to virological suppression (,6 and 6 months) with virological rebound. Because initial cART regimens were selected by choice rather than by chance, an analysis using propensity scores was conducted to limit potential biases. A 1:1 matching algorithm 7 was used to match patients based on age, initiation year of cART, sex, mode of HIV transmission, hepatitis C or hepatitis B coinfection, CDC stage, baseline CD4, NtRTI backbone in addition to baseline HIV-1 RNA or time to virological suppression within a calliper of 0.1 SD of the logit of the propensity score. Subanalyses for each specific third agent were also performed and associated adjusted HRs (aHRs) of baseline HIV-1 RNA and time to virological suppression as well as their 95% CI were plotted. We performed sensitivity analyses using two other definitions of virological rebound (either a single HIV-1 RNA .50 copies/mL or .200 copies/mL), stratified by participating centres, as well as with a more-detailed grouping of the third agent (INI, efavirenz, darunavir/ritonavir, lopinavir/ritonavir or atazanavir/ritonavir). Cox models using data from patients with no antiretroviral drug switch before virological suppression were additionally computed. All tests of significance were two-sided and P ,0.05 was taken to be significant. We used R software version 3.0.2 for the analyses. 8 
Results
Of the 13792 patients who started cART during the study period, 10023 fulfilled inclusion criteria and were analysed (Figure 1 ).
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Patients not achieving virological suppression more frequently had AIDS, and had lower CD4 count and higher HIV-1 RNA at baseline (Table S1 , available as Supplementary data at JAC Online). Baseline patients' characteristics were significantly different in the three groups, although CD4 cell counts and HIV-1 RNA differences were relatively minimal ( Table 1 ). The INI group included 536 patients on raltegravir (72.8%), 154 on elvitegravir/cobicistat (22.0%) and 46 on dolutegravir (5.2%). The median follow-up from cART initiation was 51.3 months (IQR 29.3-73.4), and was significantly shorter for INI ( Table 1 ). The mean number of HIV-1 RNA measures per year of follow-up ranged between 3.0 and 3.7 in the three groups (P , 0.001). Median time to virological suppression was 4.24 (IQR 2.66-6.91) months (Table S2 ). During 411436 patientmonths of follow-up, confirmed virological rebound was observed in 1329 (13.3%) patients, corresponding to 3.88 confirmed virological rebounds per 100 patient-years of follow-up.
Time to confirmed virological rebound according to time to viral suppression
On the basis of the Kaplan-Meier estimates, the time to confirmed virological rebound was shorter in patients with a delay in achieving initial virological suppression and in patients receiving PI/r or efavirenz, compared with INI (log-rank test, P , 0.001 and P " 0.014 respectively) (Figure 2a and b) . For the INI group, we observed a trend towards a lower risk of virological rebound if virological suppression was achieved within the first 3 months compared with between 3 and 6 months (aHR 0.47; 95% CI: 0.20-1.13; P " 0.088).
Time to confirmed virological rebound according to baseline viral load
The time to confirmed virological rebound was significantly shorter in patients with high baseline HIV-1 RNA (log-rank test, P , 0.001) (Figure 2c ). However, the time by which 90% of patients remained free of virological rebound did not differ between patients with baseline HIV-1 RNA ,10000 copies/mL or between 10000 and 100000 copies/mL (39.4 months, 95% CI 33.7-45.5 and 34.6 months, 95% CI 28.9-38.2, respectively), or in those with baseline HIV-1 RNA between 100000 and 500000 copies/mL or .500000 copies/mL (13.3 months, 95% CI 11.7-16.1 and 11.2 months, 95% CI 9.2-13.3, respectively).
Factors associated with a higher risk of virological rebound
Factors associated with a higher risk of virological rebound were aged 40 years at cART initiation, risk category other than MSM, CDC stage B or C, baseline HIV-1 RNA .100000 copies/mL, time to achieve initial virological suppression 6 months, NtRTIs backbone other than tenofovir/emtricitabine or abacavir/lamivudine, and type of cART (Table 2 ). Significant associations of virological rebound with both baseline viral load and time to virological suppression were confirmed by the propensity score matching 
Risk of virological rebound according to type of cART
Risk of virological rebound was lower for efavirenz or INI than for PI/r (aHR 0.76; 95% CI 0.66-0.87; P , 0.001; and 0.56; 95% CI 0.40-0.77; P , 0.001, respectively) ( Table 2 ). In the PI/r, efavirenz and INI groups, aHRs for virological rebound were 1.36 (95% CI 1.19-1.56), 1.28 (0.98-1.68) and 1.25 (0.60-2.57) in patients with baseline HIV-1 RNA .100000 copies/mL (Figure 4a ), and 1.87 (95% CI 1.65-2.13), 2.27 (1.76-2.92) and 3.34 (1.57-7.11) in patients for whom time to achieve initial virological suppression was 6 months, respectively (Figure 4b ). aHRs for time to virological rebound were not different for ritonavir-boosted atazanavir, darunavir or lopinavir ( Figure S1 ).
Sensitivity analyses
In sensitivity analyses, considering virological rebound as either a single HIV-1 RNA .200 copies/mL or as a single HIV-1 RNA
.50 copies/mL, differences in estimates for time to virological rebound according to time to virological suppression or cART regimen remained unchanged (Tables S3-S5) . Interestingly, baseline HIV-1 RNA 100000 copies/mL was only weakly predictive of virological rebound in the analysis where virological rebound was defined as a single HIV-1 RNA .200 copies/mL (HR of 1.10, 95% CI 0.99-1.22, P " 0.078). In analysis where patients switching cART prior to obtaining virological suppression were excluded, differences between the regimen groups were even more pronounced than in the primary analysis (Table S6) . Similar results were found in the analyses with further adjustment on site (Table S7) . Finally, crude and aHRs for virological rebound did not change after exclusion of the 147 (1.47% of the total) patients enrolled in to a clinical trial (data not shown).
Discussion
Our study is the largest observational cohort to evaluate the impact of pre-cART HIV-1 RNA and of delay to obtain virological suppression on subsequent risk of virological rebound, according to Raffi et al.
the cART regimen. With advances in antiretroviral therapy and more potent, convenient and tolerable regimens, virological suppression is achieved in most people infected with HIV. Our reallife data, in a large cohort of unselected consecutive patients seeking care in reference centres, confirm that .90%, i.e. 92.5%, of patients achieve virological suppression to a level of HIV RNA ,50 copies/mL whatever the initial first-line regimen, with either efavirenz, a PI/r or an INI. Recommended optimal initial regimens are two NtRTIs plus an INI, mainly based on potency and more rapid virological suppression. 2, 4, 9, 10 Since this key goal of virological suppression of HIV treatment is nowadays almost always achieved, the main focus is now to maintain long-term virological success to ensure wellbeing and normal quality of life. Virological rebound remains a risk in patients on long-term cART, particularly in the context of decreased adherence and/or of initial higher plasma HIV RNA. 11 In our study, younger age and symptomatic HIV infection were associated with virological rebound. Poorer virological outcomes in younger patients, males or those infected by other means than homosexual male contact might reflect their lower adherence to cART. 12, 13 We found a relationship between level of baseline HIV-1 RNA and time to virological rebound; however, the difference was highly significant for patients with baseline HIV-1 RNA , or .100000 copies/mL, and there was no difference in the intermediate strata (100000-500000 versus .500000, and ,10000 versus 10000-100000). This confirms that the threshold of 100000 copies/mL to define patients at higher risk of treatment failure is totally relevant for clinical practice. Indeed, such patients are not more prone to fail to achieve virological suppression, they do it more slowly, but are at higher risk (aHR 1.35) of secondary failure rebound, which could be related to a higher HIV Virological rebound and first-line antiretrovirals JAC burden, whence less forgiveness for a suboptimal regimen, or to periods of lower adherence. When looking at the class of initial cART, the higher risk of virological rebound in patients with high baseline HIV-1 RNA (.100000 copies/mL) was seen for patients on PI/r but not for those on INI or efavirenz. We also observed a higher, although not statistically significant, risk of virological rebound in patients started on INI who achieved virological suppression between 3 and 6 months rather than in the first 3 months of therapy. These results suggest that because of the INI's intrinsic higher potency and more rapid virological efficacy, their long-term success is less impacted by pre-cART HIV-1 RNA level, in contrast to what is seen with the PI class, and adds a further argument to position INI preferentially as first-line cART in patients with baseline HIV-1 RNA .100000 copies/mL. 10 Raffi et al.
rebound. When virological rebound was defined at 200 copies/mL, there was no impact of baseline HIV-1 RNA. This raises the recurrent question on how to define virological rebound. The Department of Health and Human Services guidelines still define virological failure as a confirmed HIV-1 RNA .200 copies/mL, 14 although there is no consensus on how to manage patients with persistent HIV RNA levels above the lower limit of detection but ,200 copies/mL. Other guidelines differ in this respect and cohort studies on clinical and virological outcomes in treated HIV-1-infected patients provide conflicting results. [15] [16] [17] A recent analysis of the Antiretroviral Therapy Cohort Collaboration in .15000 patients with 3 years follow-up showed only a weak association between low-level viraemia of HIV-1 RNA between 50 and 199 copies/mL and subsequent virological failure (aHR 1.38, 95% CI 0.96-2.00). 18 Indeed, 5% of patients on cART experience persistent episodes of low-level viraemia, between 50 and 200 copies/mL, particularly when receiving PI/r. 19, 20 Most of these patients subsequently obtain or return to HIV-1 RNA ,50 copies/mL without treatment change. 21 The risk of emergence of drug resistance during these low-level viraemia episodes may differ between drugs, drug classes and drug combinations that have different potency or genetic barriers. [22] [23] [24] Once patients have achieved virological suppression, it might be expected that maintenance of suppression is independent of the time needed to achieve virological suppression. The fact that this is not the case and that patients who achieve virological suppression .6 months after initiating cART have almost a 2-fold risk of further virological rebound, independent of pre-cART HIV-1 RNA level or their firstline regimen, suggests different hypotheses and might have important implications for clinical care. This could be the consequence of suboptimal drug exposure because of low adherence or drug-drug interaction or other pharmacokinetic reasons, 14 which would explain why patients take a longer time to obtain initial success and, therefore are more prone to subsequent rebound. Longer time to virological suppression could also reflect a higher HIV reservoir, not fully captured by the level of baseline plasma HIV-1 RNA, 25 which would translate to a more fragile status with regards to maintenance of prolonged virological suppression. Another hypothesis is based on the possibility of minority resistant variants to either drug of the initial regimen. 26 The consequences in terms of clinical management are that patients receiving firstline PI/r or with baseline HIV-1 RNA .100000 copies/mL or who achieve virological suppression after .6 months, are at higher risk of virological rebound. Consequently, these patients deserve closer virological monitoring and continuous support and counselling for cART adherence, as well as therapeutic drug monitoring. Our study has some limitations. First, the sample size for the INI class is much lower than that of the patients treated with the other two classes, because of more recent availability of this class, and these patients have shorter follow-up. However, because of concordance of results within the different sensitivity analyses performed, we believe our findings are quite robust. Second, the choice of first-line Virological rebound and first-line antiretrovirals JAC cART was not randomized and, as seen with the difference in baseline characteristics, might have been dictated by some baseline characteristics, such as CDC stage, baseline HIV RNA or presumed difficulties in adherence. This bias is probably limited by the propensity score approach used. The calendar effect, with increase of INI use and decrease of efavirenz in the latter period, reflects changes in guidelines in recent years. However, even if baseline characteristics were highly significantly different because of the very large number of patients in the three groups, they appeared minimal and analyses were adjusted for potential confounders. Furthermore, the propensity score sensitivity analysis was concordant with the crude and adjusted models. Third, we did not capture adherence data or adverse events, which might affect outcomes. In any case, our analysis was done on an intention to treat basis, to reflect the real-life situation. We did not analyse data on viral genotype at the start of treatment and at the time of the rebound. However, genotypic testing is recommended before initiating ART in France and our study was not designed to assess the consequences of virological rebound but the factors associated with virological rebound for each class of ART. In conclusion, although not performed within a randomized setting, our results suggest that risk of virological rebound after achieving suppression is higher for PI/r-than for efavirenz-or INI-based regimens. A baseline HIV-1 RNA .100000 copies/mL is associated with increased risk of virological rebound following initial suppression, when the initial regimen is a PI/r ! two NtRTIs, independent of the delay in obtaining virological suppression. Not achieving virological suppression after 6 months of first-line cART is associated with increased risk of virological rebound after achieving suppression, depending on the initial regimen, ranging from 1.9-to 3.3-fold. Nowadays, when INI represents the gold standard for first-line ART, baseline HIV RNA seems to have less impact on virological rebound, which remains associated with time to virological suppression .6 months, however. 
